0000000000148115

AUTHOR

D.l. Baeten

showing 2 related works from this author

A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients

2002

OBJECTIVES: To identify genes which are more highly expressed in the peripheral blood mononuclear cells (PBMC) of patients with spondyloarthropathy (SpA), rheumatoid arthritis (RA) and psoriatic arthritis (PsA), in comparison to normal subjects. METHODS: A 588-gene microarray was used as a screening tool to select a panel of such genes from PBMC of these subjects and of normal subjects. Results were then validated by reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: The following genes were more highly expressed in arthritis patients than in normal subjects: macrophage differentiation marker MNDA (myeloid nuclear differentiation antigen), MRP8 and MRP14 (migratory inhibitor…

AdultGenetic MarkersMaleCCR1Receptors CXCR4AdolescentSpondyloarthropathyArthritisPeripheral blood mononuclear cellArthritis RheumatoidPsoriatic arthritisRheumatologymedicineHumansSpondylitis AnkylosingPharmacology (medical)AgedOligonucleotide Array Sequence AnalysisReverse Transcriptase Polymerase Chain Reactionbusiness.industryJanus kinase 3Arthritis PsoriaticSynovial MembraneMNDAInterleukinDNAMiddle Agedmedicine.diseaseAntigens DifferentiationChemokine CXCL12ImmunologyLeukocytes MononuclearFemalebusinessChemokines CXCRheumatology (Oxford, England)
researchProduct

FRI0150 Mtor blockade by rapamycin decreases arthritis and spondylitis development and severity in hla-b27 transgenic rats

2018

Career situation of first and presenting author Student for a master or a PhD. Introduction TNF and IL-17A have been demonstrated as key inflammatory cytokines in Spondyloarthritis (SpA), whereas targeting bone remodeling remains an unmet clinical need in SpA. The mammalian target of rapamycin (mTOR) regulates IL-17 expression and osteogenesis and could therefore be a promising therapeutic target in SpA. Objectives To investigate if blockade of mTOR with rapamycin inhibits the pathological processes in inflammation and bone in SpA. Methods Cytokines were measured by ELISA in the supernatant from SpA patient PBMCs stimulated with anti-CD3/CD28, with various concentrations of rapamycin. SpA F…

musculoskeletal diseases030203 arthritis & rheumatologyHLA-B27business.industryArthritis030209 endocrinology & metabolismInflammationPharmacologymedicine.diseaseBlockadeProinflammatory cytokineBone remodeling03 medical and health sciences0302 clinical medicinemedicineTumor necrosis factor alphamedicine.symptombusinessPI3K/AKT/mTOR pathwayFRIDAY, 15 JUNE 2018
researchProduct